Clinical trial
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's…
NCT02783573 · AstraZeneca, Industry · Terminated
Key facts
| NCT number | NCT02783573 |
|---|---|
| Title | A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia |
| Official title | A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia |
| Acronym | DAYBREAK-ALZ |
| Lead sponsor | AstraZeneca, Industry |
| Collaborators | Eli Lilly and Company Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Drug |
| Interventions | Lanabecestat, Placebo |
| Enrollment | 1,722 |
| Start date | Jul 1, 2016 |
| Primary completion | Sep 28, 2018 |
| Completion | Sep 28, 2018 |
| First posted | May 26, 2016 |
| Last update posted | Dec 3, 2019 |
| Countries | Canada, China, Czechia, Denmark, France, Germany, Italy, Japan, Mexico, Netherlands, Poland, Portugal and 6 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: